Microbes on the surface of the skin help the immune system to respond to injury and heal wounds.
Immunity research have historically focused on the response to pathogens and inflammation, and so relatively little is known about how our own microbiota interact with and regulate the immune system. Yasmine Belkaid at the National Institute of Health in Bethesda, Maryland, and her colleagues set out to understand how the immune system senses and responds to microbes living on the body.
SkinBioTherapeutics (LON:SBTX) is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.